Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cytos Biotechnology AG
ClinicalTrials.gov Identifier:
NCT00500786
First received: July 12, 2007
Last updated: August 20, 2012
Last verified: August 2012

July 12, 2007
August 20, 2012
November 2004
September 2006   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00500786 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb
Not Provided

This is a multi-center, randomized, placebo-controlled, time-lagged, parallel-group study in healthy and hypertensive subjects to evaluate safety and tolerability of the vaccine CYT006-AngQb. The trial is double-blind for active vs. placebo within each treatment arm, but open with respect to AngQb dose escalation.

In the first arm, 16 healthy normotensive volunteers are treated with a one dose regimen consisting of a single s.c. injection of 100µg of AngQb or placebo. Upon satisfying safety and tolerability profile, as judged by the independent safety monitoring board, arm two is enrolled.

In arm two 36 patients with mild to moderate hypertension receive three s.c. injections of 100µg CYT006-AngQb (24 patients) or placebo (12 patients). The second and third injections are given 4 and 12 weeks after the first injection, respectively. Upon satisfying safety and tolerability profile, as judged by the independent safety monitoring board, arm three is enrolled.

In arm three 36 patients with mild to moderate hypertension receive three s.c. injections of 300µg CYT006-AngQb (24 patients) or placebo (12 patients). The second and third injections are given 4 and 12 weeks after the first injection, respectively.

The primary objective of the trial is to evaluate safety / tolerability of 3 dose regimens of CYT006-AngQb in healthy volunteers and patients with mild to moderate essential hypertension. Secondary objectives include the assessment of pharmacodynamic effects and their dose-response (immunogenicity and biomarkers of the renin-angiotensin system), and the exploration of clinical efficacy (effects on systolic and diastolic blood pressure)

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Essential Hypertension
Biological: CYT006-AngQb
  • Experimental: 100 mcg CYT006-AngQb Healthy Volunteers
    Intervention: Biological: CYT006-AngQb
  • Experimental: 100 mcg CYT006-AngQb Hypertensives
    Intervention: Biological: CYT006-AngQb
  • Experimental: 300 mcg CYT006-AngQb Hypertensives
    Intervention: Biological: CYT006-AngQb
  • Placebo Comparator: Placebo Healthy Volunteers
  • Placebo Comparator: Placebo Hypertensives
Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Müller P, Jennings GT, Wagner F, Bachmann MF. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008 Mar 8;371(9615):821-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
88
April 2007
September 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with untreated mild-to-moderate essential hypertension, clinically diagnosed according to the World Health Organization criteria (systolic blood pressure =140-179 mm Hg and/or diastolic blood pressure =90-109 mm Hg on 3 consecutive occasions; standardized after 5 minutes in sitting position)
  • Patients with newly diagnosed essential hypertension or previously treated patients from whom antihypertensive therapy can be safely withdrawn for the duration of the study.
  • 18 to 65 years of age, males and non-reproductive females (surgically sterilized or post-menopausal)
  • Written informed consent
  • Patient is willing and able to comply with all trial requirements

Exclusion Criteria:

  • Secondary hypertension
  • Severe essential hypertension
  • Current pharmacological treatment that could affect blood pressure
  • Significant renal insufficiency [Serum creatinine > 159 µmol/L (> 1.8 mg/dl)]
  • History of cerebrovascular disease
  • Type 1 Diabetes or poorly controlled Type 2 Diabetes
  • Body mass index (BMI) >32
  • Total cholesterol > 6.9 mmol/L (> 266 mg/dl)
  • Triglycerides > 3.5 mmol/L ( > 174.3 mg/dl)
  • Autoimmune diseases or severe allergies
  • Patients with a history of HIV infection, AIDS, hepatitis B or C, or other immunosuppressive disorders
  • Current diagnosis or a history of malignancy
  • Drug or alcohol abuse within the past 2 years
  • Pregnancy or breastfeeding
  • Present history of mental diseases
  • Participation in any drug trial within three month of onset of current trial
  • Previous participation in a clinical trial with a Qb based vaccine (DerQb, NicQb, AllQb)
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00500786
CYT006-AngQb 01
Yes
Cytos Biotechnology AG
Cytos Biotechnology AG
Not Provided
Principal Investigator: Frank D Wagner, MD Parexel International, Berlin, Germany
Cytos Biotechnology AG
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP